Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Prostate cancer

Radium-223: a new treatment option for bone-metastatic CRPC

Nature Reviews Urology volume 10, pages 630–631 (2013)Cite this article

Subjects

Radium-223 is an emitter of high-energy α particles that binds selectively to areas of high bone turnover. In a recently published phase III trial, it prolonged overall survival of patients with symptomatic, castration-resistant prostate cancer with bone metastases and, as a result, has gained FDA approval for this indication.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Parker, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213–223 (2013).

    Article  CAS  PubMed  Google Scholar 

  2. Bruland, O. S., Nilsson, S., Fisher, D. R. & Larsen, R. H. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin. Cancer Res. 12, 6250s–6257s (2006).

    Article  CAS  PubMed  Google Scholar 

  3. Henriksen, G., Breistol, K., Bruland, O. S., Fodstad, O. & Larsen, R. H. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 62, 3120–3125 (2002).

    CAS  PubMed  Google Scholar 

  4. Henriksen, G., Fisher, D. R., Roeske, J. C., Bruland, O. S. & Larsen, R. H. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J. Nucl. Med. 44, 252–259 (2003).

    CAS  PubMed  Google Scholar 

  5. Lewington, V. J. Bone-seeking radionuclides for therapy. J. Nucl. Med. 46 (Suppl. 1), 38S–47S (2005).

    CAS  PubMed  Google Scholar 

  6. Liepe, K. Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer. Curr. Opin. Investig. Drugs 10, 1346–1358 (2009).

    CAS  PubMed  Google Scholar 

  7. Nilsson, S. et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 8, 587–594 (2007).

    Article  CAS  PubMed  Google Scholar 

  8. Nilsson, S. et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur. J. Cancer 48, 678–686 (2012).

    Article  CAS  PubMed  Google Scholar 

  9. Parker, C. C. et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra-223) in patients with bone metastases and castration-resistant prostate cancer. Eur. Urol. 63, 189–197 (2013).

    Article  CAS  PubMed  Google Scholar 

  10. Hafeez, S. & Parker, C. Radium-223 for the treatment of prostate cancer. Expert Opin. Invest. Drugs 22, 379–387 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Internal Medicine, C353 Med Inn Building, SPC 5848, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, 48109–5848, MI, USA

    Petros D. Grivas

  2. Department of Urology, Room 5308, Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, 48109–5848, MI, USA

    Evan T. Keller

Authors
  1. Petros D. Grivas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Evan T. Keller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Evan T. Keller.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grivas, P., Keller, E. Radium-223: a new treatment option for bone-metastatic CRPC. Nat Rev Urol 10, 630–631 (2013). https://doi.org/10.1038/nrurol.2013.232

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2013.232

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing